Zobrazeno 1 - 10
of 23
pro vyhledávání: '"Elisabeth A, de Blieck"'
Autor:
Elizabeth McCusker, Michael P. McDermott, Wai Lun Alan Fung, Andrew McGarry, Merit Cudkowicz, Elisabeth A. de Blieck, Karl Kieburtz, Jing Peng, Coordinators
Publikováno v:
Neurology. 92(14)
ObjectiveMost suicidality literature in Huntington disease (HD) is based on natural history studies or retrospective reviews, but reports on risk factors from clinical trials are limited.MethodsWe analyzed 609 participants from 2CARE, a randomized, d
Autor:
Kelly L. Andrzejewski, Madhurima Majumder, Elisabeth A. de Blieck, Michael P. McDermott, Merit Cudkowicz, Haruhiko Banno, Peggy Auinger, Alyssa Murphy, Nazem Atassi
Publikováno v:
Journal of Huntington's disease. 6(2)
BACKGROUND Excellent retention in Huntington disease (HD) clinical trials is essential for testing new therapies. The stage of disease, cognitive status, and availability of a care partner may influence retention in HD clinical trials. OBJECTIVE We s
Autor:
Dai Watanabe, Elisabeth A. de Blieck, Mitsuaki Kitano, Kazunori Hosoe, M. Flint Beal, Padmaja Yerramilli-Rao, Iwao Funahashi, Karl Kieburtz, Merit Cudkowicz
Publikováno v:
International Journal of Toxicology. 31:58-69
To support phase III testing of coenzyme Q10 (CoQ10) in humans, we conducted pharmacokinetic and toxicology studies in beagle dogs. Following single gavage administration of CoQ10 at 600, 1200, 1800, or 2400 mg/kg per d no obvious dose response was o
Autor:
Frederick J. Marshall, Elisabeth A. de Blieck, Paul G. Rothberg, Jennifer Cialone, Amy Vierhile, Erika F. Augustine, Nicole Newhouse, Jonathan W. Mink, Heather R. Adams, Jennifer M. Kwon
Publikováno v:
Journal of Inherited Metabolic Disease. 34:1075-1081
Juvenile neuronal ceroid lipofuscinosis (JNCL; CLN3 disease; Batten disease) is an autosomal recessive neurodegenerative disease of childhood that typically presents at school age with vision loss followed by progressive cognitive decline, motor dysf
Autor:
Sam Frank, Michele Goldstein, Tammie Kelsey, Merit Cudkowicz, Kimberly L. Ferrante, Elisabeth A. de Blieck, Joseph Weber, Linda Metakis, Bernard Ravina, Ira Shoulson, Robert J. Ferrante, Karl Kieburtz, Danna Jennings, Francis O. Walker, Arthur Watts, Peter Como, Michael P. McDermott, Vicki Hunt, H. Christopher Hyson, Carol Zimmerman, Susan E. Browne, Susan Daigneault, M. Flint Beal, Kristyn Newhall
Publikováno v:
Movement Disorders. 25:1924-1928
Coenzyme Q10 (CoQ(10)), a potential neuroprotective compound, was previously investigated at a dosage of 600 mg/day in Huntington's disease (HD) patients and demonstrated a trend toward slowing disease progression. Higher CoQ(10) dosages may prove be
Autor:
Jennifer M. Kwon, Jonathan W. Mink, Rachel Jordan, Christopher A. Beck, Elisabeth A. de Blieck, Heather R. Adams, Frederick J. Marshall, David A. Pearce, Erika Levy, Erika F. Augustine, Amy Vierhile
Publikováno v:
Developmental Medicine & Child Neurology. 52:637-643
Aim The primary aim of this investigation was to examine genotype and clinical phenotype differences in individuals with juvenile neuronal ceroid lipofuscinosis (JNCL) who were homozygous for a common disease-causing deletion or compound heterozygous
Autor:
Cynthia R. Howard, Elisabeth A. de Blieck, Cynthia B. ten Hoopen, Fred M. Howard, Bruce P. Lanphear, Ruth A. Lawrence
Publikováno v:
Pediatrics. 104:1204-1207
Background. To prevent breastfeeding problems, cup-feeding has been recommended as a method of providing medically necessary supplemental feedings to breastfed infants. Objectives. To compare amounts ingested, administration time, and infant physiolo
Autor:
Jennifer Cialone, Nicole Newhouse, Leon S. Dure, Heather R. Adams, Katherine Rose, Elisabeth A. de Blieck, Erika Levy, Jonathan W. Mink, Amy Vierhile, Jennifer M. Kwon, Denia Ramirez-Montealegre, Erika F. Augustine, Frederick J. Marshall
Publikováno v:
Journal of inherited metabolic disease. 35(3)
Juvenile neuronal ceroid lipofuscinosis (JNCL; CLN3 disease; Batten disease) is an autosomal recessive neurodegenerative disease of childhood. Symptoms typically present at school age with vision loss followed by progressive cognitive decline, motor
Autor:
H Christopher, Hyson, Karl, Kieburtz, Ira, Shoulson, Michael, McDermott, Bernard, Ravina, Elisabeth A, de Blieck, Merit E, Cudkowicz, Robert J, Ferrante, Peter, Como, Sam, Frank, Carol, Zimmerman, Kimberly, Ferrante, Kristyn, Newhall, Danna, Jennings, Tammie, Kelsey, Francis, Walker, Vicki, Hunt, Susan, Daigneault, Michele, Goldstein, Joseph, Weber, Arthur, Watts, M Flint, Beal, Susan E, Browne, Linda J, Metakis
Publikováno v:
Movement disorders : official journal of the Movement Disorder Society. 25(12)
Coenzyme Q10 (CoQ(10)), a potential neuroprotective compound, was previously investigated at a dosage of 600 mg/day in Huntington's disease (HD) patients and demonstrated a trend toward slowing disease progression. Higher CoQ(10) dosages may prove be
Autor:
Heather R, Adams, Christopher A, Beck, Erika, Levy, Rachel, Jordan, Jennifer M, Kwon, Frederick J, Marshall, Amy, Vierhile, Erika F, Augustine, Elisabeth A, de Blieck, David A, Pearce, Jonathan W, Mink
Publikováno v:
Developmental medicine and child neurology. 52(7)
The primary aim of this investigation was to examine genotype and clinical phenotype differences in individuals with juvenile neuronal ceroid lipofuscinosis (JNCL) who were homozygous for a common disease-causing deletion or compound heterozygous. Th